Risk factors of isolated antibody against core antigen of hepatitis B virus: Association with HIV infection and age but not hepatitis C virus infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 2, 2010, Pages 122-128

  Liang, Shiou Haur ^a   Chen, Tai Jui ^a   Lee, Susan Shin Jung ^b,c   Tseng, Fan Chen ^d   Huang, Chun Kai ^a   Lai, Chung Hsu ^a   Chiou, Chou Ping ^e   Wang, Jiun Ling ^a   Chung, Hsing Chun ^a   Lin, Jiun Nong ^a   Kuo, Yi Chi ^a   Lin, Hsi Hsun ^a,c  

^a E DA HOSPITAL   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e I SHOU UNIVERSITY   (Taiwan)

Author keywords

HBV; HCV; HIV; Isolated anti HBc; Risk factors

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; METHADONE;

ADULT; AGE; ANTIBODY ISOLATION; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DRUG ABUSE; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; SEROPREVALENCE; VACCINATION;

ADULT; AGE FACTORS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 77953081754     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181daafd5     Document Type: Article

References (54)

1. Grob P, Jilg W, Bornhak H, et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol. 2000;62:450-455.
2. Berger A, Doerr HW, Rabenau HF, et al. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology. 2000;43:71-76.
3. Davaro RE, Cheeseman SH, Keroack MA, et al. The significance of isolated antibody to hepatitis B core antigen seropositivity in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;23:189-190.
4. Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36: 681-686.
5. Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis. 2003;36:1602-1605. (Pubitemid 36783346)
6. Hung CC, Hsiao CF. Isolated antibody to hepatitis B core antigen in individuals infected with HIV-1. Clin Infect Dis. 2003;37:1275-1276; Author reply 1277.
7. Neau D, Winnock M, Galperine T, et al. Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med. 2004; 5:171-173.
8. French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. JInfectDis. 2007;195:1437-1442.
9. Hadler SC, Murphy BL, Schable CA, et al. Epidemiological analysis of the significance of low-positive test results for antibody to hepatitis B surface and core antigens. J Clin Microbiol. 1984;19:521-525.
10. AuBuchon JP, Sandler SG, Fang CT, et al. American Red Cross experience with routine testing for hepatitis B core antibody. Transfusion. 1989;29:230-232.
11. Joller-Jemelka HI, Wicki AN, Grob PJ. Detection of HBs antigen in "anti-HBc alone" positive sera. J Hepatol. 1994;21:269-272.
12. Jilg W, Sieger E, Zachoval R, et al. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol. 1995;23:14-20.
13. Greub G, Frei PC. Isolated antibody to hepatitis B core is associated with hepatitis C virus co-infection. Clin Microbiol Infect. 2000;6:629.
14. Wedemeyer H, Cornberg M, Tegtmeyer B, Frank H, Tillmann HL, Manns MP. Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. Clin Microbiol Infect. 2004; 10:70-72.
15. Wiedmann M, Liebert UG, Oesen U, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology. 2000; 31:230-234.
16. Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology. 2001;34:194-203.
17. Sheng WH, Kao JH, Chen PJ, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;45:1221-1229.
18. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2:1129-1133.
19. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135:796-800.
20. Lee SD, Chan CY, Wang YJ, et al. Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology. 1991;13:830-833.
21. Wu JS, Lu CF, Liu WT, et al. Prevalence of antibodies to hepatitis C virus (anti-HCV) in different populations in Taiwan. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1991;24:55-60.
22. Chang CJ, Ko YC, Liu HW. Seroepidemiology of hepatitis C virus infection among drug abusers in southern Taiwan. J Formos Med Assoc. 1998;97:826-829.
23. Chang CJ, Lin CH, Lee CT, et al. Hepatitis C virus infection among shortterm intravenous drug users in southern Taiwan. Eur J Epidemiol. 1999; 15:597-601.
24. Lai MY. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan. Intervirology. 2006;49:91-95.
25. Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106: 148-155.
26. Twu SJ, Huang YF, Lai AC, et al. Update and projection on HIV/AIDS in Taiwan. AIDS Educ. Prev. 2004;16:53-63.
27. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology. 2001;34:204-206.
28. Moir S, Ogwaro KM, Malaspina A, et al. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A. 2003;100:6057-6062.
29. Lin HH, Shih YL, Liu YC, et al. An epidemic of HIV type I CRF07-BC infection among injection drug users in Taiwan. J Acquir Immune Defic Syndr. 2006;42:248-255.
30. Chen YM, Kuo SH. HIV-1 in Taiwan. Lancet. 2007;369:623-625.
31. Liu JY, Lin HH, Liu YC, et al. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. Clin Infect Dis. 2008;46:1761-1768.
32. Lee HC, Ko NY, Lee NY, et al. Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in Southern Taiwan, 2000-2005: upsurge in hepatitis C virus infections among injection drug users. J Formos Med Assoc. 2008;107: 404-411.
33. Perez-Rodriguez MT, Sopena B, Crespo M, et al. Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients. World J Gastroenterol. 2009;15:1237-1241.
34. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6-S9.
35. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49:S138-S145.
36. Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis. 2005;40(Suppl 5):S263-S269.
37. Knoll A, Hartmann A, Hamoshi H, et al. Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance. World J Gastroenterol. 2006;12:1255-1260.
38. Averhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998;15:1-8.
39. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22-26.
40. De Maria N, Colantoni A, Friedlander L, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000;95:3529-3536.
41. Hofer M, Joller-Jemelka HI, Grob PJ, et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis. 1998;17:6-13.
42. Nunez M, Rios P, Perez-Olmeda M, et al. Lack of 'Aoccult' hepatitis B virus infection in HIV-infected patients. AIDS. 2002;16:2099-2101.
43. Gandhi RT, Wurcel A, McGovern B, et al. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr. 2003;34:439-441. (Pubitemid 37444474)
44. Wagner AA, Denis F, Weinbreck P, et al. Serological pattern 'Aanti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS. 2004;18: 569-571.
45. Neau D, Winnock M, Jouvencel AC, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis. 2005;40: 750-753.
46. Tsui JI, French AL, Seaberg EC, et al. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin Infect Dis. 2007;45:736-740.
47. Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology. 2007;132:1287-1293.
48. Chen DS, Hsu NH, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 1987;257:2597-2603.
49. Chien YC, Jan CF, Kuo HS, et al. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev. 2006;28:126-135.
50. Sun HY, Ko WC, Tsai JJ, et al. Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination. Am J Gastroenterol. 2009;104:877-884.
51. Liang SH, Lo YC, Lin HH, et al. Seroprevalence of viral hepatitis and infectious complications among human immunodeficiency virus-infected injection drug users at a referral hospital. J Microbiol Immunol Infect. 2008;41:200-208.
52. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284: 450-456.
53. Ponde RA, Cardoso DD, Ferro MO. The underlying mechanisms for the 'Aanti-HBc alone' serological profile. Arch Virol. 2010;155:149-158.
54. Abbott. ARCHITECT Anti-HBc Assay Manual. Abbott Park: Abbott Laboratories; 2003.